Correction: Systemic administration of glibenclamide fails to achieve therapeutic levels in the brain and cerebrospinal fluid of rodents (PLoS ONE (2015) 10: 7 (e0134476) DOI: 10.1371/journal.pone.0134476);Systemic administration of glibenclamide fails to achieve therapeutic levels in the brain and cerebrospinal fluid of rodents

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Lahmann, Carolina ^a,b   Kramer, Holger B ^a   Ashcroft, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELACRIDAR; GLIBENCLAMIDE; GLUCOSE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; ISOFLURANE; ANTIDIABETIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PELLET; DRUG PENETRATION; DRUG TREATMENT FAILURE; EPILEPSY; FEMALE; GLUCOSE BLOOD LEVEL; INTRACRANIAL DRUG ADMINISTRATION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NEWBORN DIABETES MELLITUS; NONHUMAN; RAT; RIGHTING REFLEX; SEX DIFFERENCE; SYSTEMIC THERAPY; TANDEM MASS SPECTROMETRY; WITHDRAWAL REFLEX; YOUNG ADULT; ANIMAL; BRAIN; CEREBROSPINAL FLUID; MASS SPECTROMETRY; METABOLISM;

ANIMALS; BRAIN; FEMALE; GLYBURIDE; HYPOGLYCEMIC AGENTS; MALE; MASS SPECTROMETRY; RATS;

EID: 84942155748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0215989     Document Type: Erratum

References (44)

1. Henquin JC. The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work? Diabetologia. 1992;35:907-912. PMID: 1451945
2. Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia. Springer-Verlag; 2003;46:875-891. doi: 10.1007/s00125-003-1143-3 PMID: 12819907
3. Pearson JG. Pharmacokinetics of glyburide. Am J Med. 1985;79:67-71.
4. Rafiq M, Flanagan SE, Patch A-M, Shields BM, Ellard S, Hattersley AT, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. American Diabetes Association; 2008;31:204-209. doi: 10.2337/dc07-1785 PMID: 18025408
5. Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol. 2003;81:133-176. PMID: 12565699
6. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350:1838-1849. doi: 10.1056/NEJMoa032922 PMID: 15115830
7. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54:2503-2513. PMID: 16123337
8. Edghill EL, Flanagan SE, Ellard S. Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11. Rev Endocr Metab Disord. Springer US; 2010;11:193-198. doi: 10.1007/s11154-010-9149-x PMID: 20922570
9. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia. Springer-Verlag; 2006;49:2559-2563. doi: 10.1007/s00125-006-0407-0 PMID: 17047922 Glibenclamide Administration Fails to Reach Effective Levels in Brain PLOS
10. Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L, et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol. Nature Publishing Group; 2007;3:640-645. doi: 10.1038/ncpneuro0640 PMID: 17982434
11. Shimomura K, Hörster F, De Wet H, Flanagan SE, Ellard S, Hattersley AT, et al. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology. Lippincott Williams & Wilkins; 2007;69:1342-1349. doi: 10.1212/01.wnl.0000268488.51776.53 PMID: 17652641
12. Koster JC, Kurata HT, Enkvetchakul D, Nichols CG. DEND mutation in Kir6.2 (KCNJ11) reveals a flexible N-terminal region critical for ATP-sensing of the KATP channel. Biophys J. Elsevier; 2008;95:4689-4697. doi: 10.1529/biophysj.108.138685 PMID: 18708460
13. Slingerland AS, Hurkx W, Noordam K, Flanagan SE, Jukema JW, Meiners LC, et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med. Blackwell Publishing Ltd; 2008;25:277-281. doi: 10.1111/j.1464-5491.2007.02373.x PMID: 18307455
14. Battaglia D, Lin Y-W, Brogna C, Crinò A, Grasso V, Mozzi AF, et al. Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation. Pediatr Diabetes. 2012;13:656-660. doi: 10.1111/j.1399-5448.2012.00874.x PMID: 22694282
15. Masia R, Koster JC, Tumini S, Chiarelli F, Colombo C, Nichols CG, et al. An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. Diabetes. American Diabetes Association; 2007;56:328-336. doi: 10. 2337/db06-1275 PMID: 17259376
16. Gurgel LC, Crispim F, Noffs MHS, Belzunces E, Rahal MA, Moisés RS. Sulfonylrea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene: improvement in glycemic control and neurological function. Diabetes Care. American Diabetes Association; 2007;30:e108-e108. doi: 10.2337/dc07-1196 PMID: 17965292
17. Manna Della T, Battistim C, Radonsky V, Savoldelli RD, Damiani D, Kok F, et al. Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene. Arq Bras Endocrinol Metabol. 2008;52:1350-1355. PMID: 19169493
18. Zwaveling-Soonawala N, Hagebeuk EE, Slingerland AS, Ris-Stalpers C, Vulsma T, Van Trotsenburg AS. Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation. Diabetologia. Springer-Verlag; 2011;54:469-471. doi: 10.1007/s00125-010-1981-8 PMID: 21109997
19. Itoh S, Matsuoka H, Yasuda Y, Miyake N, Suzuki K, Yorifuji T, et al. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas. J Pediatr Endocrinol Metab. 2013;26:143-146. doi: 10.1515/jpem-2012-0236 PMID: 23382304
20. Takanaga H, Murakami H, Koyabu N, Matsuo H, Naito M, Tsuruo T, et al. Efflux transport of tolbutamide across the blood-brain barrier. J Pharm Pharmacol. 1998;50:1027-1033. PMID: 9811164
21. Tournier N, Saba W, Cisternino S, Peyronneau M-A, Damont A, Goutal S, et al. Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide. AAPS J. Springer US; 2013;15:1082-1090. doi: 10.1208/s12248-013-9514-2 PMID: 23907487
22. Gedeon C, Behravan J, Koren G, Piquette-Miller M. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006;27:1096-1102. doi: 10.1016/j.placenta.2005. 11.012 PMID: 16460798
23. Bessadok A, Garcia E, Jacquet H, Martin S, Garrigues A, Loiseau N, et al. Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins. J Biol Chem. American Society for Biochemistry and Molecular Biology; 2011;286:3552-3569. doi: 10.1074/jbc. M110.155200 PMID: 21098040
24. Clark RH, McTaggart JS, Webster R, Mannikko R, Iberl M, Sim XL, et al. Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin. Science. American Association for the Advancement of Science; 2010;329:458-461. doi: 10.1126/science.1186146 PMID: 20595581
25. Girard CA, Wunderlich FT, Shimomura K, Collins S, Kaizik S, Proks P, et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. American Society for Clinical Investigation; 2009;119:80-90. doi: 10.1172/JCI35772 PMID: 19065048
26. Hopfgartner G, Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom Rev. Wiley Subscription Services, Inc., A Wiley Company; 2003;22:195-214. doi: 10.1002/mas.10050 PMID: 12838545
27. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355:467-477. doi: 10.1056/NEJMoa061759 PMID: 16885550
28. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt). Mary Ann Liebert, Inc. 2 Madison Avenue Larchmont, NY 10538 USA; 2005;14:19-29. doi: 10.1089/jwh.2005.14. 19
29. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. American Society for Pharmacology and Experimental Therapeutics; 2009;76:215-228. doi: 10.1124/mol.109.056705 PMID: 19483103
30. Proks P, De Wet H, Ashcroft FM. Molecular mechanism of sulphonylurea block of K (ATP) channels carrying mutations that impair ATP inhibition and cause neonatal diabetes. Diabetes. American Diabetes Association; 2013;62:3909-3919. doi: 10.2337/db13-0531 PMID: 23835339
31. Golstein PE, Boom A, Van Geffel J, Jacobs P, Masereel B, Beauwens R. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999;437:652-660. PMID: 10087141
32. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999;59:4237-4241. PMID: 10485464
33. Ward KW, Azzarano LM. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9, 10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-isoquinolinyl) ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. J Pharmacol Exp Ther. American Society for Pharmacology and Experimental Therapeutics; 2004;310:703-709. doi: 10.1124/jpet.104.068288 PMID: 15056727
34. Karibe T, Hagihara-Nakagomi R, Abe K, Imaoka T, Mikkaichi T, Yasuda S, et al. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res. Springer US; 2015;32:1634-1647. doi: 10.1007/s11095-014-1563-4 PMID: 25380981
35. Remedi MS, Nichols CG. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. Groop L, editor. PLoS Med. Public Library of Science; 2008;5:e206. doi: 10.1371/journal.pmed.0050206 PMID: 18959471
36. Shawahna R, Uchida Y, Decleves X, Ohtsuki S, Yousif S, Dauchy S, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm. American Chemical Society; 2011;8:1332-1341. doi: 10.1021/mp200129p PMID: 21707071
37. Do TM, Noel-Hudson M-S, Ribes S, Besengez C, Smirnova M, Cisternino S, et al. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1.40 at the mouse blood-brain barrier. J Alzheimers Dis. IOS Press; 2012;30:155-166. doi: 10.3233/JAD-2012-112189 PMID: 22391220
38. Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, et al. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med. Society of Nuclear Medicine; 2013;54:1181-1187. doi: 10.2967/jnumed.112. 118232 PMID: 23833270
39. Sapunar D, Kostic S, Banozic A, Puljak L. Dorsal root ganglion. a potential new therapeutic target for neuropathic pain. J Pain Res. Dove Press; 2012;5:31-38. doi: 10.2147/JPR. S26603 PMID: 22375099
40. Yao X, Chang AY, Boulpaep EL, Segal AS, Desir GV. Molecular cloning of a glibenclamide-sensitive, voltage-gated potassium channel expressed in rabbit kidney. J Clin Invest. American Society for Clinical Investigation; 1996;97:2525-2533. doi: 10.1172/JCI118700 PMID: 8647945
41. Myngheer N, Allegaert K, Hattersley A, McDonald T, Kramer H, Ashcroft FM, et al. Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes. Diabetes Care. American Diabetes Association; 2014;37:3333-3335. doi: 10.2337/dc14-1247 PMID: 25231897
42. Fendler W, Pietrzak I, Brereton MF, Lahmann C, Gadzicki M, Bienkiewicz M, et al. Switching to sulphonylureas in children with iDEND syndrome caused by KCNJ11 mutations results in improved cerebellar perfusion. Diabetes Care. American Diabetes Association; 2013;36:2311-2316. doi: 10.2337/dc12-2166 PMID: 23462667
43. Mourre C, Widmann C, Lazdunski M. Sulfonylurea binding sites associated with ATP-regulated K+ channels in the central nervous system: autoradiographic analysis of their distribution and ontogenesis, and of their localization in mutant mice cerebellum. Brain Res. 1990;519:29-43. PMID: 2118822
44. Karschin C, Ecke C, Ashcroft FM, Karschin A. Overlapping distribution of K (ATP) channel-forming Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain. FEBS Lett. 1997;401:59-64. PMID: 9003806